niacinamide has been researched along with Adenocystic Carcinoma in 2 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is the first anti-angiogenic agent to demonstrate activity in RMSGC patients, particularly in some histotypes such as HG-MEC, SDC and adenocarcinoma, NOS." | 5.22 | A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. ( Alfieri, S; Bergamini, C; Bossi, P; Civelli, E; Cortelazzi, B; Dagrada, GP; Granata, R; Imbimbo, M; Licitra, L; Lo Vullo, S; Locati, LD; Mariani, L; Mirabile, A; Morosi, C; Orlandi, E; Perrone, F; Pilotti, S; Quattrone, P; Resteghini, C; Saibene, G, 2016) |
| "Sorafenib was only reasonably well tolerated, and 13 patients (57%) experienced grade 3 toxicity." | 2.80 | Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. ( Bonington, S; Denton, K; Homer, J; Lee, LW; Mak, SK; Silva, P; Slevin, NJ; Swindell, R; Sykes, AJ; Thomson, DJ; Yap, BK, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thomson, DJ | 1 |
| Silva, P | 1 |
| Denton, K | 1 |
| Bonington, S | 1 |
| Mak, SK | 1 |
| Swindell, R | 1 |
| Homer, J | 1 |
| Sykes, AJ | 1 |
| Lee, LW | 1 |
| Yap, BK | 1 |
| Slevin, NJ | 1 |
| Locati, LD | 1 |
| Perrone, F | 1 |
| Cortelazzi, B | 1 |
| Bergamini, C | 1 |
| Bossi, P | 1 |
| Civelli, E | 1 |
| Morosi, C | 1 |
| Lo Vullo, S | 1 |
| Imbimbo, M | 1 |
| Quattrone, P | 1 |
| Dagrada, GP | 1 |
| Granata, R | 1 |
| Resteghini, C | 1 |
| Mirabile, A | 1 |
| Alfieri, S | 1 |
| Orlandi, E | 1 |
| Mariani, L | 1 |
| Saibene, G | 1 |
| Pilotti, S | 1 |
| Licitra, L | 1 |
2 trials available for niacinamide and Adenocystic Carcinoma
| Article | Year |
|---|---|
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck.
Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Disease Progression; Female; Humans; Male; Middle Aged; Niac | 2015 |
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepider | 2016 |